key: cord-0770464-qzk9egna
authors: Assimakopoulos, Stelios F.; Seintis, Fotios; Marangos, Markos
title: Pentoxifylline and complicated COVID-19: a pathophysiologically based treatment proposal
date: 2020-05-30
journal: Med Hypotheses
DOI: 10.1016/j.mehy.2020.109926
sha: f6035f33660fcc517d586bc89dcfae275f09fb7c
doc_id: 770464
cord_uid: qzk9egna

nan

To the Editor, Accumulating evidence suggests that a subgroup of patients with COVID-19 might suffer from severe complications, such as acute respiratory distress syndrome (ARDS), coagulopathy with thromboses and acute cardiac injury, increasing the risk of mortality. A proposed common pathogenetic mechanism for these complications is a SARS-CoV-2induced proinflammatory state (cytokine storm syndrome-CSS) [1] . Immunomodulatory medications such as inhibitors of interleukin (IL)-6 (tocilizumab) or IL-1 (anakinra) have been proposed as potential treatments for the CSS.

Pentoxifylline (PTX), a non-specific inhibitor of phosphodiesterases and wellestablished hemorheological factor, exhibits pluripotent properties which could be of value in the context of COVID-19-associated complications. First, PTX inhibits the synthesis of diverse pro-inflammatory cytokines (tumour necrosis factor-α IL-1, IL-6) and prevents the activation, cell proliferation, adhesion, polarisation and hemotaxis of T cells and neutrophils [2] . Second, PTX antagonizes the inhibitory effect of TNF-α on surfactant synthesis by human type II pneumocytes, which is a pivotal mechanism of ARDS pathogenesis [3] . Third, PTX inhibits platelet aggregation and promotes the fibrinolytic activity, which might decrease the risk of thromboses [4] . Fourth, it exerts cardioprotective actions mediated by its beneficial hemorheological, anti-platelet and anti-inflammatory properties [5] . Its antiviral activity against SARS-CoV-2 has not been tested, but PTX exerts potent in vitro activity against HIV, herpes simplex virus, rotavirus and tick-borne encephalitis virus [6] .

To our opinion, this profile of actions of PTX is identically harmonized with several levels of the pathophysiology of COVID-19-associated complications, justifying its trial for the prevention or treatment of severe COVID-19.

COVID-19: consider cytokine storm syndromes and immunosuppression

Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways

Effect of pentoxifylline on the inhibition of surfactant synthesis induced by TNF-alpha in human type II pneumocytes

Antithrombotic potential of pentoxifylline. A hemorheologically active drug

Effect of Pentoxifylline in Ameliorating Myocardial Injury in Patients With Myocardial Infarction Undergoing Thrombolytic Therapy: A Pilot Randomized Clinical Trial

Pentoxifylline and severe acute respiratory syndrome (SARS): a drug to be considered